Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06140771 · ClinicalTrials.gov registry record · NA
A Clinical Study to Assess the Gingivitis Effects of Various Dentifrices
A NA study, sponsored by Procter and Gamble.
- Completed
- Registry status
- NA
- Development phase
- 115
- Enrollment target
NCT06140771: Completed NA study, sponsored by Procter and Gamble.
NCT06140771 is a NA study that has completed, run by Procter and Gamble. The registered enrollment target is 115 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06140771, a NA study, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- NA
- Development phase
- 115 participants
- Enrollment target
Study Summary
The objective of this learning clinical study is to assess the gingivitis effects of four different dentifrices over a 3-month period.
Primary Outcome
Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).
Interventions
- DRUG 0.76% Sodium Monofluorophosphate Dentifrice
- DRUG 0.454% Stannous Fluoride Dentifrice
- DRUG 1.15% Sodium Monofluorophosphate Dentifrice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2021-10-20 |
| Est. Completion | 2022-02-06 |
| Phase | NA |
What the finished NCT06140771 record still lists
NCT06140771 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which 0.76% Sodium Monofluorophosphate Dentifrice is the first listed.
NCT06140771 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06140771 about?
NCT06140771 is a clinical study titled "A Clinical Study to Assess the Gingivitis Effects of Various Dentifrices". The objective of this learning clinical study is to assess the gingivitis effects of four different dentifrices over a 3-month period.
What is the current status of trial NCT06140771?
This trial is currently completed. It is a NA study. The enrollment target is 115 participants. The study started on 2021-10-20. Estimated completion is 2022-02-06.
What interventions are being tested in trial NCT06140771?
The interventions under investigation include: 0.76% Sodium Monofluorophosphate Dentifrice (DRUG), 0.454% Stannous Fluoride Dentifrice (DRUG), 1.15% Sodium Monofluorophosphate Dentifrice (DRUG).
Who is sponsoring clinical trial NCT06140771?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06140771's enrollment target sits among peer trials
115 810th of 2000 higher than 1,190 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI